Markus Follmann

USPTO Granted Patents = 52 (Patent Applications = 19)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 41 (Patent Applications = 51)

Average Co-Inventor Count = 8.0

ph-index = 12

Forward Citations = 358(Granted Patents)

DiyaCoin

= 0.09

Inventors with similar research interests:

Location History:

Wulfrath, DE (2012)
Frankfurt-am-Main, DE (2014 - 2017)
Wülfrath, DE (2011 - 2019)
Köln, DE (2014 - 2019)
Cologne, DE (2016 - 2024)

Company Filing History:

21 out of 378

Bayer Pharma Aktiengesellschaft

patents

18 out of 721

Bayer Intellectual Property Gmbh

where one patent can have more than one assignee

Years Active: 2011-2025

where 'Filed Patents' based on already Granted Patents

52 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12427131 - Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof (2025-09-30),

2. 12064429 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2024-08-20),

3. 11439642 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2022-09-13),

4. 11166932 - Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof (2021-11-09),

5. 10736896 - Substituted 5-fluoro-1H-pyrazolopyridines and their use (2020-08-11),

6. 10265314 - SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis (2019-04-23),

7. 10189856 - Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) (2019-01-29),

8. 10053428 - 5-aminotetrahydroquinoline-2-carboxylic acids and their use (2018-08-21),

9. 10052312 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2018-08-21),

10. 9993476 - Substituted 5-flouro-1H-pyrazolopyridines and their use (2018-06-12),

11. 9776997 - 3-aryl-substituted imidazo[1,2-A]pyridines and their use (2017-10-03),

12. 9771360 - Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use (2017-09-26),

13. 9688699 - 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines (2017-06-27),

14. 9688636 - 5-aminotetrahydroquinoline-2-carboxylic acids and their use (2017-06-27),

15. 9624214 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2017-04-18),

Title: Innovations and Contributions of Markus Follmann in Cardiovascular Research

Introduction

Markus Follmann, located in Köln, Germany, is a prolific inventor known for his significant contributions to the field of medicinal chemistry. With an impressive portfolio of 51 patents, he has been at the forefront of innovations targeting the treatment and prevention of various diseases, particularly cardiovascular disorders.

Latest Patents

Among his latest innovations are the patents for "Substituted 5-fluoro-1H-pyrazolopyridines and their use." These patents relate to novel substituted compounds that have potential applications in the treatment and prophylaxis of diseases. The processes for their preparation and use in developing medicaments specifically aimed at addressing cardiovascular disorders mark a notable advancement in pharmaceutical research.

Career Highlights

Throughout his career, Follmann has worked with renowned companies such as Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. His roles at these institutions have allowed him to leverage his expertise in creating therapeutic solutions and enhancing the understanding of medicinal properties.

Collaborations

Follmann has collaborated with esteemed colleagues, including Johannes-Peter Stasch and Frank Wunder. These partnerships have fostered a collaborative environment that nurtures innovation and accelerates the development of new medical therapies.

Conclusion

Markus Follmann's contributions to the field of pharmaceutical innovation, especially in the area of cardiovascular treatment, underscore the importance of research and development in improving healthcare outcomes. His extensive patent portfolio reflects his dedication to advancing medical science and the potential to positively impact patient lives through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.